A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Summary

This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Timeline

Start

2022-09-13

Primary completion

2024-06-14

Completion

2024-06-14

Drugs

Indications